> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# NuCana Phase 3 Bilary Tract Cancer Study
- URL: https://www.fdaweb.com/nucana-phase-3-bilary-tract-cancer-study/
- Published: 2019-10-25T12:00:00.000Z
- Updated: 2026-09-15T01:59:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145346

FDA has authorized NuCana to begin a Phase 3 study (nutide:121) of the investigational drug Acelarin in combination with cisplatin for patients with previously untreated locally advanced or metastatic biliary tract cancer. The 828-patient study will randomize patients to receive either a combination of Acelarin plus cisplatin or the current standard of care regimen, gemcitabine plus cisplatin. “In the Phase Ib ABC-08 study, we observed an approximate doubling of the response rate with Acelarin plus cisplatin compared to previously reported data for gemcitabine plus cisplatin,” the company says. The Phase 3 study will evaluate overall survival and objective response rate.